NO20020792L - Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid - Google Patents

Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid

Info

Publication number
NO20020792L
NO20020792L NO20020792A NO20020792A NO20020792L NO 20020792 L NO20020792 L NO 20020792L NO 20020792 A NO20020792 A NO 20020792A NO 20020792 A NO20020792 A NO 20020792A NO 20020792 L NO20020792 L NO 20020792L
Authority
NO
Norway
Prior art keywords
combination
treatment
clonidine
opioid
restless leg
Prior art date
Application number
NO20020792A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020792D0 (no
Inventor
Hans-Michael Brecht
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20020792D0 publication Critical patent/NO20020792D0/no
Publication of NO20020792L publication Critical patent/NO20020792L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO20020792A 1999-08-19 2002-02-18 Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid NO20020792L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19938823A DE19938823A1 (de) 1999-08-19 1999-08-19 Medikamentöse Behandlung des Restless Leg Syndroms
PCT/EP2000/007719 WO2001013903A2 (de) 1999-08-19 2000-08-09 Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid

Publications (2)

Publication Number Publication Date
NO20020792D0 NO20020792D0 (no) 2002-02-18
NO20020792L true NO20020792L (no) 2002-02-18

Family

ID=7918572

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020792A NO20020792L (no) 1999-08-19 2002-02-18 Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid

Country Status (21)

Country Link
US (1) US20010053777A1 (pl)
EP (1) EP1210076A2 (pl)
JP (1) JP2003513014A (pl)
KR (1) KR20020020273A (pl)
CN (1) CN1368878A (pl)
AR (1) AR025329A1 (pl)
AU (1) AU6836500A (pl)
BR (1) BR0013355A (pl)
CA (1) CA2382648A1 (pl)
CO (1) CO5190708A1 (pl)
CZ (1) CZ2002516A3 (pl)
DE (1) DE19938823A1 (pl)
IL (1) IL147643A0 (pl)
MX (1) MXPA02001295A (pl)
NO (1) NO20020792L (pl)
PE (1) PE20010738A1 (pl)
PL (1) PL364871A1 (pl)
SK (1) SK2452002A3 (pl)
TR (1) TR200200450T2 (pl)
UY (1) UY26296A1 (pl)
WO (1) WO2001013903A2 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
CN1418099A (zh) * 2000-04-21 2003-05-14 法玛西雅厄普约翰美国公司 用于治疗肌纤维疼痛和慢性疲劳综合征的精选化合物
CN1450898A (zh) 2000-04-21 2003-10-22 法玛西雅厄普约翰美国公司 用于治疗纤维肌痛和慢性疲劳综合症的化合物
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
US8338442B2 (en) 2001-03-30 2012-12-25 Toray Industries, Inc. Remedies for psychoneurosis
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
WO2004000312A2 (de) * 2002-06-19 2003-12-31 Solvay Pharmaceuticals Gmbh Arzneimittel zur behandlung von eine inhibition oder aktivitätsverminderung von ph-wert-regulierenden bikarbonat-transporter-proteinen erfordernden erkrangungen
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
ES2239196T3 (es) 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
CA2594373A1 (en) * 2005-01-28 2006-08-03 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
WO2008079727A2 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
EP2363116A1 (en) * 2008-06-25 2011-09-07 US Worldmeds LLC Sustained-release formulations comprising lofexidine for oral delivery
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
JP2015523989A (ja) * 2012-06-11 2015-08-20 サイコジェニックス・インコーポレーテッドＰｓｙｃｈｏｇｅｎｉｃｓ Ｉｎｃ． パーキンソン病の処置に伴う運動不全及び運動障害副作用の処置
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
KR101948779B1 (ko) 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US20190358208A1 (en) * 2016-09-13 2019-11-28 Mindlab LLC Medicine combinations and treatment of restless leg syndrome
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
RS63302B1 (sr) * 2020-05-04 2022-07-29 Bioprojet Pharma Upotreba dopaminskih d3 delimičnih agonista za tretiranje poremećaja centralnog nervnog sistema
CN115154448B (zh) * 2022-08-04 2024-01-30 谭竞 一种治疗不宁腿综合征的药物及其制备方法和应用
WO2025255416A1 (en) * 2024-06-05 2025-12-11 TMTRx, Inc. Fentanyl and fentanyl analogue overdose reversal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
KR20020020273A (ko) 2002-03-14
PE20010738A1 (es) 2001-07-16
AU6836500A (en) 2001-03-19
US20010053777A1 (en) 2001-12-20
SK2452002A3 (en) 2002-06-04
EP1210076A2 (de) 2002-06-05
NO20020792D0 (no) 2002-02-18
CN1368878A (zh) 2002-09-11
IL147643A0 (en) 2002-08-14
UY26296A1 (es) 2001-04-30
TR200200450T2 (tr) 2002-08-21
BR0013355A (pt) 2002-04-30
CZ2002516A3 (cs) 2002-05-15
JP2003513014A (ja) 2003-04-08
WO2001013903A3 (de) 2001-08-23
DE19938823A1 (de) 2001-02-22
PL364871A1 (pl) 2004-12-27
MXPA02001295A (es) 2002-08-12
CA2382648A1 (en) 2001-03-01
WO2001013903A2 (de) 2001-03-01
CO5190708A1 (es) 2002-08-29
AR025329A1 (es) 2002-11-20

Similar Documents

Publication Publication Date Title
NO20020792L (no) Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid
DE60335294D1 (de) Dlung des extrapyramidalen syndroms
MXPA03003912A (es) Tratamientos nuevos para el sindrome de piernas inquietas.
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
EP1575414A4 (en) METHOD AND DEVICES FOR DETECTING AND THERAPY OF ATHEROMATOUS PLAQUE
HUP0401740A2 (hu) N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
CY1105014T1 (el) Ο συνδυασμος ενος αναστολεα επαναπροσληψης σεροτονινης κι ενος 5-ht2c ανταγωνιστη, αντιστροφου αγωνιστη ή μερικου αγωνιστη
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
MX9700030A (es) Administracion de pirenzipina, matilescopolamina y otros antagonistas del receptor mascurinico para el tratamiento de transtornos del metabolismo de lipidos.
NO20020793L (no) Virkestoffkombinasjon med clonidin
NO20045240L (no) Transepikutan administrasjonsform for a behandle restless legs syndromet
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
NO933524L (no) Krystallisk tiagabinhydrokloridmonohydrat samt fremstilling og anvendelse derav
SE9803760D0 (sv) Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
EA200300844A1 (ru) Использование ингибиторов il-18 для лечения и/или профилактики заболевания сердца
CY1107062T1 (el) ΧΡΗΣΗ ΔΡΑΣΤΙΚΩΝ ΟΥΣΙΩΝ ΜΕ ΔΡΑΣΗ ΑΓΩΝΙΣΤΗ μ-ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΚΑΙ ΔΡΑΣΗ ΑΝΤΑΓΩΝΙΣΤΗ ΥΠΟΔΟΧΕΑ ΟΠΙΟΕΙΔΩΝ ΩΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΜΕΣΑ ΣΥΝΔΥΑΣΜΟΥ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
MXPA04002539A (es) Combatientes de los receptores de la acetilcolina nicotinica en el tratamiento del sindrome de pierna inquietas.
WO2004019881A3 (en) Hypocretin administration as a treatment for obesity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application